DISEASES OF THE NERVOUS SYSTEM AND COVID-19
The research purpose was to assess the impact of concomitant diseases of the nervous system (NNS) on the outcome of COVID - 19 treatment in hospitals. Materials and research methods. 1087 patients with COVID - 19 hospitalized in hospitals in Makhachkala were examined. The patients were divided into 2 groups: the main group had concomitant BNS - 106 patients; the control group without these diseases - 981 patients. The structure of concomitant BNS includes encephalopathy, stroke, polyneuropathy and others. Quantitative indicators were assessed using the Shapiro - Wilk test (n=50) or the Kolmogorov - Smirnov test (n<50). Results. When comparing age depending on the presence of BNS, statistically significant differences were established (in the main group, Me 72 years, in the control group, Me 62 years; p<0.001, Mann - Whitney U - test). Among patients with COVID - 19, pensioners and disabled people made up the majority in the main (86.7%) and control groups (66.2%; p=0.049). In the main group, the incidence of respiratory failure and its severity are higher than in the control group (p<0.001; Mann - Whitney U - test). Pharmacological and epidemiological analysis of the treatment of COVID - 19 showed a worsening of the prognosis of the disease when patients were prescribed psycholeptics and psychoanaleptics (p=0.001; Pearson's Chi - square). The chances of survival in the control group were 3.5 times higher than in the main group, the difference in odds was statistically significant (95% CI: 2.134 - 5.638; p<0.001; Pearson's Chi - square). Conclusion. Our studies suggest that the involvement of the nervous system in COVID - 19 may be the cause of the worsening of the course and prognosis of the disease. It is more expedient to conduct further in - depth studies of the damage to the nervous system in COVID - 19, which will supplement the information currently available.